Inflammatory microenvironment contributes to epithelial-mesenchymal transition in gastric cancer

被引:0
|
作者
Hui-Ying Ma [1 ]
Xin-Zhou Liu [1 ]
Chun-Min Liang [1 ]
机构
[1] Lab of Tumor Immunology, Department of Anatomy and Histology and Embryology, Shanghai Medical College of Fudan University
基金
美国国家科学基金会;
关键词
Gastric cancer; Inflammation; Epithelialmesenchymal transition; Microenvironment; Immune cells;
D O I
暂无
中图分类号
R735.2 [胃肿瘤];
学科分类号
100214 ;
摘要
Gastric cancer(GC) is the fifth most common malignancy in the world. The major cause of GC is chronic infection with Helicobacter pylori(H. pylori). Infection with H. pylori leads to an active inflammatory microenvironment that is maintained by immune cells such as T cells, macrophages, natural killer cells, among other cells. Immune cell dysfunction allows the initiation and accumulation of mutations in GC cells, inducing aberrant proliferation and protection from apoptosis. Meanwhile, immune cells can secrete certain signals, including cytokines, and chemokines, to alter intracellular signaling pathways in GC cells. Thus, GC cells obtain the ability to metastasize to lymph nodes by undergoing the epithelial-mesenchymal transition(EMT), whereby epithelial cells lose their epithelial attributes and acquire a mesenchymal cell phenotype. Metastasis is a leading cause of death for GC patients, and the involved mechanisms are still under investigation. In this review, we summarize the current research on how the inflammatory environment affects GC initiation and metastasis via EMT.
引用
收藏
页码:6619 / 6628
页数:10
相关论文
共 50 条
  • [41] The Effect of Dihydroartemisinin on the Malignancy and Epithelial-Mesenchymal Transition of Gastric Cancer Cells
    Li, Nan
    Zhang, Suyun
    Luo, Qiong
    Yuan, Fang
    Feng, Rui
    Chen, Xiangqi
    Yang, Sheng
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2019, 20 (09) : 719 - 726
  • [42] Inhibition or Reversal of the Epithelial-Mesenchymal Transition in Gastric Cancer: Pharmacological Approaches
    Kozak, Joanna
    Forma, Alicja
    Czeczelewski, Marcin
    Kozyra, Pawel
    Sitarz, Elzbieta
    Radzikowska-Buchner, Elzbieta
    Sitarz, Monika
    Baj, Jacek
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (01) : 1 - 23
  • [43] Epithelial-Mesenchymal Transition and Breast Cancer
    Wu, Yanyuan
    Sarkissyan, Marianna
    Vadgama, Jaydutt V.
    JOURNAL OF CLINICAL MEDICINE, 2016, 5 (02)
  • [44] Epithelial-mesenchymal transition in ovarian cancer
    Vergara, Daniele
    Merlot, Benjamin
    Lucot, Jean-Philippe
    Collinet, Pierre
    Vinatier, Denis
    Fournier, Isabelle
    Salzet, Michel
    CANCER LETTERS, 2010, 291 (01) : 59 - 66
  • [45] Lung cancer and epithelial-mesenchymal transition
    Toshi Menju
    Hiroshi Date
    General Thoracic and Cardiovascular Surgery, 2021, 69 : 781 - 789
  • [46] Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting
    Sistigu, Antonella
    Di Modugno, Francesca
    Manic, Gwenola
    Nistico, Paola
    CYTOKINE & GROWTH FACTOR REVIEWS, 2017, 36 : 67 - 77
  • [47] Epithelial-mesenchymal transition and cancer.
    Arvelo, Francisco
    Sojo, Felipe
    INVESTIGACION CLINICA, 2023, 64 (03): : 379 - 404
  • [48] Lung cancer and epithelial-mesenchymal transition
    Menju, Toshi
    Date, Hiroshi
    GENERAL THORACIC AND CARDIOVASCULAR SURGERY, 2021, 69 (05) : 781 - 789
  • [49] Epithelial-mesenchymal transition in development and cancer
    Micalizzi, Douglas S.
    Ford, Heide L.
    FUTURE ONCOLOGY, 2009, 5 (08) : 1129 - 1143
  • [50] The Inflammatory Profile of the Tumor Microenvironment, Orchestrated by Cyclooxygenase-2, Promotes Epithelial-Mesenchymal Transition
    Gomez-Valenzuela, Fernan
    Escobar, Enrico
    Perez-Tomas, Ricardo
    Montecinos, Viviana P.
    FRONTIERS IN ONCOLOGY, 2021, 11